Kobo Biotech Ltd-$
Kobo Biotech Ltd-$ (KOBO) last reported results for the quarter ended Jun 2024, with sales of ₹0 crore and net profit of ₹-1.33 crore. The stock last traded at ₹3.72, a market capitalisation of ₹8.86 crore. Over the past 52 weeks the stock has ranged between ₹1.99 and ₹9.99. Figures are as of 6 Oct 2026 and are not real time.
Kobo Biotech Ltd-$ share price and key metrics
- Current price
- ₹3.72
- Market cap
- ₹8.86 cr
- Book value
- ₹-58
- ROE
- %
- ROCE
- -126%
- Dividend yield
- 0.00%
- 52w high / low
- 9.99/1.99
Metrics as of 6 Oct 2026. Not real time.
Track Kobo Biotech Ltd-$
Cruxal reads every Kobo Biotech Ltd-$ filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Kobo Biotech Ltd-$ growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- %
- 10 Years
- 6%
- 5 Years
- 12%
- 3 Years
- 18%
- TTM
- -6%
- 10 Years
- -6%
- 5 Years
- -2%
- 3 Years
- 11%
- 1 Year
- 62%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- %
Kobo Biotech Ltd-$ quarterly results
| ₹ crore | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.21 | 0.17 | 0.79 | 0.23 | 0.2 | 0.2 | 0.25 | 0.34 |
| Operating profit | -0.21 | -0.17 | -0.79 | -0.23 | -0.2 | -0.2 | -0.25 | -0.34 |
| OPM % | — | — | — | — | — | — | — | — |
| Other income | 0 | 0 | 0 | 0.02 | 0 | 0 | 0 | 0.02 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.89 | 1.03 | 1 | 1.01 | 1.02 | 1.03 | 1.01 | 1.01 |
| Profit before tax | -1.1 | -1.2 | -1.79 | -1.22 | -1.22 | -1.23 | -1.26 | -1.33 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | -1.1 | -1.19 | -1.79 | -1.23 | -1.22 | -1.23 | -1.26 | -1.33 |
| EPS (₹) | -0.46 | -0.50 | -0.75 | -0.52 | -0.51 | -0.52 | -0.53 | -0.56 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Kobo Biotech Ltd-$ annual results
| ₹ crore | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 32.54 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | 4.8 | -4.05 | -3.02 | -1.72 | -0.69 | -2.79 | -10.51 | -1.5 | -0.88 | -1.24 |
| OPM % | 14.75% | — | — | — | — | — | — | — | — | — |
| Net profit | -16.46 | -19.24 | -23.92 | -24.46 | -21.01 | -19.23 | -15.23 | -5.55 | -4.93 | -5.23 |
| EPS (₹) | -6.94 | -8.08 | -10.04 | -10.27 | -8.82 | -8.07 | -6.39 | -2.33 | -2.07 | -2.20 |
TTM is the trailing twelve months to the most recent quarter.
Kobo Biotech Ltd-$ balance sheet
| ₹ crore | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 23.73 | 23.83 | 23.83 | 23.83 | 23.83 | 23.83 | 23.83 | 23.83 | 23.83 | 23.83 |
| Reserves | -17.30 | -42.41 | -66.33 | -90.79 | -111.80 | -131.03 | -146.25 | -151.81 | -156.74 | -161.97 |
| Borrowings | 152.68 | 207.60 | 221.96 | 236.36 | 250.76 | 260.53 | 140.71 | 139.84 | 139.69 | 139.69 |
| Other liabilities | 101.36 | 63.20 | 66.48 | 70.04 | 73.54 | 77.26 | 60.89 | 63.47 | 64.62 | 70.04 |
| Total liabilities | 260.47 | 252.22 | 245.94 | 239.44 | 236.33 | 230.59 | 79.18 | 75.33 | 71.40 | 71.59 |
| Fixed assets | 87.79 | 81.01 | 74.56 | 68.42 | 62.54 | 56.91 | 41.66 | 37.59 | 33.52 | 29.44 |
| CWIP | 2.25 | 2.25 | 2.25 | 2.25 | 2.25 | 2.25 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 12.19 | 12.19 | 12.19 | 12.19 | 12.19 | 12.19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other assets | 158.24 | 156.77 | 156.94 | 156.58 | 159.35 | 159.24 | 37.52 | 37.74 | 37.88 | 42.15 |
| Total assets | 260.47 | 252.22 | 245.94 | 239.44 | 236.33 | 230.59 | 79.18 | 75.33 | 71.40 | 71.59 |
As reported by the company. Total assets equal total liabilities by construction.
Kobo Biotech Ltd-$ cash flow
| ₹ crore | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 5.62 | 32.30 | 31.47 | 20.95 | 14.48 | 2.51 | 93.76 | 0.87 | 0.20 | 4.18 |
| Cash from investing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 25.09 | 0.00 | 0.00 | 0.00 |
| Cash from financing | -5.27 | -32.76 | -31.47 | -20.95 | -14.47 | -1.08 | -120.28 | -0.87 | -0.15 | 0.00 |
| Net cash flow | 0.35 | -0.46 | 0.00 | 0.00 | 0.00 | 1.43 | -1.43 | 0.00 | 0.05 | 4.18 |
| Free cash flow | 5.62 | 32.30 | 31.47 | 20.95 | 14.48 | 2.51 | 106.65 | 0.87 | 0.20 | 4.18 |
| CFO / operating profit | 117% | -798% | -1,042% | -1,218% | -2,099% | -90% | -892% | -58% | -23% | -337% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Kobo Biotech Ltd-$ operating ratios
| Per year | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -1.33% | -2.77% | -5.11% | -4.49% | -3.94% | -5.31% | -17.60% | -36.82% | -52.90% | -125.57% |
| Debtor days | 1,006.50 | — | — | — | — | — | — | — | — | — |
| Inventory days | 1,038.63 | — | — | — | — | — | — | — | — | — |
| Days payable | 1,092.57 | — | — | — | — | — | — | — | — | — |
| Cash conversion cycle | 952.56 | — | — | — | — | — | — | — | — | — |
| Working capital days | -251.48 | — | — | — | — | — | — | — | — | — |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Kobo Biotech Ltd-$ shareholding pattern
Promoters held 44.95% at Jun 2026, broadly unchanged since Jun 2025. DIIs 0.00%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 44.95% | 44.95% | 44.95% | 44.95% | 44.95% | 44.95% | 44.95% | 44.95% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 55.05% | 55.05% | 55.04% | 55.05% | 55.05% | 55.05% | 55.05% | 55.05% |
| No. of shareholders | 6,916 | 7,542 | 7,873 | 7,929 | 7,947 | 7,970 | 7,977 | 7,734 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.